Samsung Peptide AG publishes offer prospectus for public tender offer for PolyPeptide Group AG
Ad hoc announcements pursuant to Art. 53 LR
Baar, 31 August 2026 – PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, today announced that Samsung Peptide AG, a direct subsidiary of Samsung Biologics Co., Ltd., a leading global CDMO, has published the offer prospectus for its public tender offer for all publicly held registered shares of PolyPeptide Group AG. This follows the publication by Samsung Biologics Co., Ltd. of the pre-announcement of the public tender offer on 20 July 2026.
[…]